Clinical Trial Update: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial at Mayo Clinic evaluating low-dose selinexor in combination with choline salicylate for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Histiocytic and Dendritic Cell Neoplasm
• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Choline Salicylate (choline salicylate)
• Selinexor (selinexor)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING